deltatrials
Completed OBSERVATIONAL NCT01753024

Pancreatic Exocrine Insufficiency and Pancreatic Enzyme Supplementation in Critically Ill Adult Patients

The Incidence of Pancreatic Exocrine Insufficiency and the Benefits of Pancreatic Enzyme Supplementation in Critically Ill Adult Patients

Sponsor: Shanghai 10th People's Hospital

Updated 12 times since 2017 Last updated: Sep 4, 2018 Started: Jan 31, 2012 Primary completion: Dec 31, 2015 Completion: Dec 31, 2015
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Acute Renal Failure and Cardiac Arrest, this trial is completed. The trial is conducted by Shanghai 10th People's Hospital and has accumulated 12 data snapshots since 2012. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Study Description(click to expand)

Critically ill patients who is able to receive early enteral nutrition and estimated to stay in ICU at least four days are considered to enroll into this study. Exclusion criteria are age under 18 or over 80 years, pregnancy or breastfeeding, known exocrine pancreatic insufficiency due to pancreatitis, unresectable pancreatic cancer, cystic fibrosis, celiac disease, Zollinger-Ellison syndrome, pancreatectomy, gastrectomy and medications of somatostatin or aprotinin that directly influence pancreatic exocrine function. Informed consent documents are signed by immediate family members of the recruited patients. All study procedures are performed in accordance with the institutional guidelines for the conduct of research on human beings and approved by the Human Ethics Committee of Shanghai Tenth People's Hospital. Once the enrolled patients are admitted to the ICU, they are inserted either a nasogastric tube or a nasojejunal tube guided by electronic gastroscope according to the expected feeding time, and the position of feeding tubes is confirmed by plain abdominal radiograph. Enteral nutrition will be initiated at a rate of 25 ml/h within 24h of admission, and the infusion rate increases steadily until the prescribed nutritional requirements are achieved within 3 days. Daily nutritional requirements are calculated mainly based on the patient's body mass...

Critically ill patients who is able to receive early enteral nutrition and estimated to stay in ICU at least four days are considered to enroll into this study. Exclusion criteria are age under 18 or over 80 years, pregnancy or breastfeeding, known exocrine pancreatic insufficiency due to pancreatitis, unresectable pancreatic cancer, cystic fibrosis, celiac disease, Zollinger-Ellison syndrome, pancreatectomy, gastrectomy and medications of somatostatin or aprotinin that directly influence pancreatic exocrine function.

Informed consent documents are signed by immediate family members of the recruited patients. All study procedures are performed in accordance with the institutional guidelines for the conduct of research on human beings and approved by the Human Ethics Committee of Shanghai Tenth People's Hospital.

Once the enrolled patients are admitted to the ICU, they are inserted either a nasogastric tube or a nasojejunal tube guided by electronic gastroscope according to the expected feeding time, and the position of feeding tubes is confirmed by plain abdominal radiograph. Enteral nutrition will be initiated at a rate of 25 ml/h within 24h of admission, and the infusion rate increases steadily until the prescribed nutritional requirements are achieved within 3 days. Daily nutritional requirements are calculated mainly based on the patient's body mass index.

During the study, the details of each patient such as age, sex, BMI, admission diagnosis, and Acute Physiology and Chronic Health Evaluation II score are collected. All clinical characteristics that may cause pancreatic damage, including shock (systolic blood pressure \< 90 mmHg), tissue hypoxia (serum lactate \> 2 mmol/L), respiratory failure (PaO2 \< 60 mmHg), anemia (hemoglobin \< 90 g/L), obesity (BMI \> 30 kg/m2), biliary sludge (total bilirubin \> 17.5 μmol/L), hypertriglyceridemia (\> 1.7 mmol/L), sepsis, cardiac arrest, cardiopulmonary bypass (CPB), severe head injury, acute stroke, post-neurosurgery, diabetes, inflammatory bowel disease (IBS), mechanical ventilation and continuous renal replacement therapy (CRRT) are recorded prospectively. Medications such as propofol, valproate, metronidazole and morphine-derived drugs, which are applied for more than 24 h and might induce pancreatic damage, are also documented. Arterial blood samples are taken 3 days after admission to determine biochemical parameters. Stool samples are collected 3-5 days after the beginning of enteral nutrition and frozen at -20℃ until analysis. Some patients will undergo CT scanning and magnetic resonance cholangio-pancreatography (MRCP)to acquire histological evidence of exocrine pancreatic insufficiency.

Status Flow

~Jan 2017 – ~Aug 2017 · 7 months · monthly snapshotUnknown Status~Aug 2017 – ~Apr 2018 · 8 months · monthly snapshotUnknown Status~Apr 2018 – ~May 2018 · 30 days · monthly snapshotUnknown Status~May 2018 – ~Jun 2018 · 31 days · monthly snapshotUnknown Status~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshotUnknown Status~Oct 2018 – ~Nov 2020 · 25 months · monthly snapshotCompleted~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshotCompleted~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotCompleted~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 19 months · monthly snapshotCompleted~Jan 2026 – present · 3 months · monthly snapshotCompleted

Change History

12 versions recorded
  1. Jan 2026 — Present [monthly]

    Completed

  2. Sep 2024 — Present [monthly]

    Completed

  3. Jul 2024 — Sep 2024 [monthly]

    Completed

  4. Dec 2021 — Jul 2024 [monthly]

    Completed

  5. Jan 2021 — Dec 2021 [monthly]

    Completed

Show 7 earlier versions
  1. Nov 2020 — Jan 2021 [monthly]

    Completed

  2. Oct 2018 — Nov 2020 [monthly]

    Completed

    Status: Unknown StatusCompleted

  3. Jun 2018 — Oct 2018 [monthly]

    Unknown Status

  4. May 2018 — Jun 2018 [monthly]

    Unknown Status

  5. Apr 2018 — May 2018 [monthly]

    Unknown Status

    Phase: NANone

  6. Aug 2017 — Apr 2018 [monthly]

    Unknown Status NA

  7. Jan 2017 — Aug 2017 [monthly]

    Unknown Status NA

    First recorded

Jan 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Shanghai 10th People's Hospital
  • Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
  • Tongji Hospital
Data source: Shanghai 10th People's Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations